for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sanofi SA

SASY.PA

Latest Trade

79.35EUR

Change

0.31(+0.39%)

Volume

291,984

Today's Range

78.21

 - 

79.80

52 Week Range

67.65

 - 

95.82

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
79.04
Open
79.75
Volume
291,984
3M AVG Volume
39.88
Today's High
79.80
Today's Low
78.21
52 Week High
95.82
52 Week Low
67.65
Shares Out (MIL)
1,253.60
Market Cap (MIL)
99,508.57
Forward P/E
--
Dividend (Yield %)
3.99

Next Event

Q3 2020 Sanofi SA Earnings Call

Latest Developments

More

Sanofi: to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab)

Sanofi And Parkinson's Foundation Announce New Research Collaboration

Enzymatica Enters Agreement With Sanofi For Covering France And Italy On Common Cold Spray Coldzyme®

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sanofi SA

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.

Industry

Biotechnology & Drugs

Contact Info

54 rue la Boetie

75008

France

+33.1.53774000

https://www.sanofi.com/

Executive Leadership

Serge Weinberg

Independent Chairman of the Board

Paul Hudson

Chief Executive Officer, Member of the Executive Committee, Director

Jean-Baptiste Chasseloup de Chatillon

Chief Financial Officer, Executive Vice President, Member of the Executive Committee

Karen Linehan

Executive Vice President - Legal Affairs and General Counsel, Member of the Executive Committee

Caroline Luscombe

Executive Vice President of Human Resources, Member of the Executive Committee

Key Stats

2.04 mean rating - 26 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

35.1K

2018

34.5K

2019

36.1K

2020(E)

37.1K
EPS (EUR)

2017

5.540

2018

5.470

2019

5.990

2020(E)

5.869
Price To Earnings (TTM)
8.93
Price To Sales (TTM)
2.64
Price To Book (MRQ)
1.57
Price To Cash Flow (TTM)
7.90
Total Debt To Equity (MRQ)
39.42
LT Debt To Equity (MRQ)
33.77
Return on Investment (TTM)
11.36
Return on Equity (TTM)
9.44

Latest News

Latest News

Sanofi raises outlook as speciality care and vaccines lift sales

Sanofi raised its 2020 earnings guidance for the second time this year after posting slightly stronger-than-expected third-quarter results on Thursday, helped by growth at its speciality care and vaccines units.

Factbox: Latest on worldwide spread of the coronavirus

Germany announced plans to shut down large swathes of public life for a month on Wednesday, while France prepared to tighten controls further as COVID-19 surged across Europe and financial markets tumbled at the likely cost of a second lockdown.

Sanofi, GSK to supply vaccine doses to WHO-backed alliance

French drugmaker Sanofi <SASY.PA> and Britain's GlaxoSmithKline <GSK.L> will supply 200 million doses of their COVID-19 candidate vaccine to a global inoculation scheme backed by the World Health Organization.

BRIEF-Sanofi Says Co, GSK To Support COVAX With 200 Mln Doses Of COVID-19 Vaccine

* SANOFI SAYS CO AND GSK TO SUPPORT COVAX WITH 200 MILLION DOSES OF ADJUVANTED, RECOMBINANT PROTEIN-BASED COVID-19 VACCINE

GSK, Sanofi to make 200 mln doses available for COVID-19 vaccine alliance

French drugmaker Sanofi SA and Britain's GlaxoSmithKline plan to make 200 million doses of their COVID-19 vaccine candidate available to the vaccine allocation plan co-led by GAVI and the World Health Organization.

Sanofi reports positive animal test results for potential COVID-19 vaccine

Clinical trials of an experimental vaccine against COVID-19 which is being developed by France's Sanofi and U.S. biotech firm Translate Bio are on track to begin before the end of the year after positive results in tests on animals.

Novavax to explore combined influenza/COVID-19 vaccine for use post pandemic

Novavax Inc said on Tuesday it has set up a team of company veterans as it seeks U.S. regulatory approval for its seasonal influenza vaccine and to help develop a combined influenza/COVID-19 vaccine for use after the pandemic.

Exclusive: AstraZeneca gets partial immunity in low-cost EU vaccine deal

European governments will pay claims above an agreed limit against AstraZeneca over side-effects from its potential COVID-19 vaccine, under different terms to a deal struck with Sanofi, an EU official told Reuters.

Sanofi spokesman says has no role in COVID-19 human challenge trial

Sanofi is not involved in the COVID-19 human challenge trials reported to be launched in Britain and its potential vaccines are not being used in the trials, a spokesman for the French drugmaker said on Wednesday.

Sanofi spokesman says has no role in COVID-19 human challenge trial

Sanofi is not involved in the COVID-19 human challenge trials reported to be launched in Britain and its potential vaccines are not being used in the trials, a spokesman for the French drugmaker said on Wednesday.

Canada warns of rising COVID-19 case numbers, signs new agreements for vaccines

Canada is planning for a worst-case scenario in which a new wave of the coronavirus will drive up cases by more than 1,000 per day over the next 10 days, officials said on Tuesday.

BRIEF-Canada has signed agreement with Sanofi for up to 72 million doses Of potential COVID-19 vaccine - minister

* CANADA HAS SIGNED AN AGREEMENT FOR AN EXTRA 14 MILLION DOSES OF POTENTIAL MODERNA COVID-19 VACCINE

COVID-19 vaccine makers see EU shield against side-effect claims

Vaccine makers will be indemnified in Europe if their COVID-19 shots cause unexpected side-effects, an industry official said on Tuesday, urging European regulators to set up more predictable schemes to compensate possible victims.

EU pays $384 million for Sanofi-GSK COVID vaccine as WHO scheme deadline looms

The European Union has agreed to buy a potential COVID-19 vaccine from Sanofi and GSK in its second such deal to secure supplies, as a deadline for joining the World Health Organization's (WHO) vaccine purchase programme looms.

Roche studies Ocrevus, experimental drug in bid to defend MS franchise

Roche aims to defend its multiple sclerosis (MS) franchise from rivals Novartis and Sanofi with new studies of its $4 billion-per-year Ocrevus product and advanced trials of an experimental medicine, fenebrutinib.

Sanofi France chief sees coronavirus vaccine priced below 10 euros

A coronavirus vaccine that Sanofi <SASY.PA> is developing with Britain's GlaxoSmithKline <GSK.L> is likely to be priced at less than 10 euros ($11.80) per shot if it is approved for use, Sanofi's chief in France said on Saturday.

Sanofi France chief: future COVID-19 vaccine seen below 10 euros

Sanofi's chief in France, Olivier Bogillot, said on Saturday that its future COVID-19 vaccine was likely to be priced below 10 euros per shot.

Sanofi, GSK launch trial for COVID-19 protein-based vaccine

French drugmaker Sanofi and Britain's GlaxoSmithKline said they had started a clinical trial of their protein-based COVID-19 vaccine candidate, and aimed to reach the final testing stage by December.

Sanofi and GSK launch trial for COVID-19 protein-based vaccine

French drugmaker Sanofi and its British peer GSK have started a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical companies race to develop treatments against the coronavirus pandemic.

Sanofi, BMS must face revived whistleblower suit over Plavix marketing

A federal appeals court has revived a whistleblower lawsuit accusing Sanofi-Aventis and Bristol-Myers Squibb of falsely marketing their blood-thinner drug Plavix, finding that a lower court dismissed it based on a misreading of the False Claims Act's "first-to-file" bar.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up